Ovarian Malignant Mixed Mullerian Tumor Managed with Neoadjuvant Chemotherapy and Cytoreductive Surgery.
- Author:
Myoung Seon KANG
1
;
Seok Mo KIM
;
Ho Sun CHOI
;
You Gyoung LEE
Author Information
1. Department of Obstetrics and Gynecology, Chonnam National University College of Medicine, Gwangju, Korea.
- Publication Type:Case Report
- Keywords:
MMMT(Malignant mixed Mullerian tumor);
Ovary
- MeSH:
Chemotherapy, Adjuvant;
Cisplatin;
Drug Therapy*;
Female;
Humans;
Ovarian Neoplasms;
Ovary;
Paclitaxel;
Reference Values
- From:Korean Journal of Obstetrics and Gynecology
2004;47(2):367-371
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Malignant mixed Mullerian tumor(MMMT) of the ovary is very uncommon neoplasm consisting of both a sarcomatous and carcinomatous component. These tumors usually present in an advanced stage and are characterized by rapid growth and poor survival and appropriate treatment remained controversial. The patients with advanced stage ovarian cancer could only benefit from an optimal surgical debulking. However, the optimal cytoreductive surgery may often be difficult to achieve due to the initial extent of the disease. Thus primary surgery for this subset of patients may be questionable. So, we tried neoadjuvant Taxol and/or cis-platinum combined chemotherapy as primary treatment. At the end of neoadjuvant chemotherapy, the patient showed markedly decrease of serum CA 125 level(from 210 U/ml to 59 U/ml) and optimal cytoreductive surgery was performed. After surgery, adjuvant chemotherapy was administered and the serum CA 125 level decreased to the normal range. This case shows our experience of neoadjuvant chemotherapy followed by cytoreductive surgery and adjuvant chemotherapy in patient with primarily unresectable ovarian malignant mixed Mullerian tumor(MMMT).
